Promising new molecular targeted therapies in head and neck cancer

Kelly Dorsey, Mark Agulnik*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


Despite advances in multimodality therapies for the treatment of squamous cell carcinoma of the head and neck (SCCHN), survival rates, functional outcomes and toxicities of therapy remain poor. The recognition of the prognostic value of human papillomavirus (HPV) status, and the advent of biologically targeted therapies with potential for decreased toxicities and increased selectivity, represent significant developments in our understanding of SCCHN. Targeted agents currently approved or under investigation for SCCHN include epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab, zalutumumab, nimotuzumab), EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, lapatinib, afatanib, dacomitinib), vascular endothelial growth factor receptor (VEGFR) inhibitors (bevacizumab, sorafenib, sunitinib, vandetanib) and various inhibitors of other pathways and targets, including phosphatidylinositol 3′ kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), MET and insulin-like growth factor receptor (IGF-1R). On-going clinical trials are evaluating these emerging agents and their combinations in the treatment of SCCHN.

Original languageEnglish (US)
Pages (from-to)315-325
Number of pages11
Issue number4
StatePublished - Mar 1 2013

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Promising new molecular targeted therapies in head and neck cancer'. Together they form a unique fingerprint.

Cite this